Patrick J. McEnany has been at the helm of Catalyst Pharmaceutical for nearly a decade, serving as CEO since 2014. With a focus in the pharmaceutical field, he has guided the company through significant growth, aligning executive pay with company...

Patrick J. McEnany has been at the helm of Catalyst Pharmaceutical for nearly a decade, serving as CEO since 2014. With a focus in the pharmaceutical field, he has guided the company through significant growth, aligning executive pay with company performance metrics. McEnany’s leadership is marked by his ability to adapt, demonstrated by multiple contract extensions over the years, ensuring stability and continuity at the company’s top level. Notably, he will retire by the end of 2023 but will continue serving as the non-Executive Chairman of the Board, indicating a commitment to the company's future even beyond his active role. His tenure has been solidified by a pay structure that includes a substantial mix of salary, performance bonuses, and vested stock, ultimately reaching a total compensation of $1 million in 2023. Under his watch, Catalyst saw impressive increases in stock value, reflecting his successful management strategies. McEnany’s approach connects financial targets and operational efficiencies directly to his team’s incentives, creating a culture of achievement that drives the company’s goals. His exit plan ensures a seamless transition, as he has communicated openly about his decision, signaling stability for employees and investors alike.